Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials

Aims To compare the long-term safety and efficacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent (EES) after percutaneous coronary interventions. Methods and results A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model by the Knapp-Hartung method was used to compute odds ratios (OR) and 95% confidence intervals (CI). The primary safety outcome of interest was the risk of definite/probable device thrombosis (DT). The primary efficacy outcome of interest was the risk of target lesion failure (TLF). Five randomized clinical trials (n = 1730) were included. Patients treated with Absorb BVS had a higher risk of definite/probable DT compared with patients treated with EES (OR 2.93, 95%CI 1.37-6.26, P = 0.01). Very late DT (VLDT) occurred in 13 patients [12/996 (1.4%, 95%CI: 0.08-2.5) Absorb BVS vs. 1/701 (0.5%, 95%CI: 0.2-1.6) EES; OR 3.04; 95%CI 1.2-7.68, P = 0.03], 92% of the VLDT in the BVS group occurred in the absence of dual antiplatelet therapy (DAPT). Patients treated with Absorb BVS had a trend towards higher risk of TLF (OR 1.48, 95%CI 0.90-2.42, P = 0.09), driven by a higher risk of target vessel myocardial infarction and ischaemia-driven target lesion revascularization. No difference was found in the risk of cardiac death. Conclusion Compared with EES, the use of Absorb BVS was associated with a higher rate of DT and a trend towards higher risk of TLF. VLDT occurred in 1.4% of the patients, the majority of these events occurred in the absence of DAPT.

[1]  I. Penn,et al.  Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study) , 1998, European heart journal.

[2]  Patrick W Serruys,et al.  Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  P. Serruys,et al.  Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents: A Prospective Cohort Study , 2012, Circulation.

[4]  Patrick W Serruys,et al.  From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? , 2012, European heart journal.

[5]  P. Serruys,et al.  Very late scaffold thrombosis after bioresorbable scaffold implantation: an unexpected new enemy on the horizon… or just a false alarm? , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  Cynthia D Mulrow,et al.  Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change , 2014, Annals of Internal Medicine.

[7]  W. Cheong,et al.  Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. , 2015, Journal of the American College of Cardiology.

[8]  Varesh Prasad,et al.  Macro- and microscale variables regulate stent haemodynamics, fibrin deposition and thrombomodulin expression , 2014, Journal of The Royal Society Interface.

[9]  F. Van de Werf,et al.  Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. , 1997, Circulation.

[10]  Katja Jasinskaja,et al.  Elaboration and Explanation ⋆ , 2011 .

[11]  F. Eberli,et al.  Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings. , 2015, Journal of the American College of Cardiology.

[12]  W. Cheong,et al.  A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. , 2015, European heart journal.

[13]  Ryo Torii,et al.  The Nidus for Possible Thrombus Formation: Insight From the Microenvironment of Bioresorbable Vascular Scaffold. , 2016, JACC. Cardiovascular interventions.

[14]  P. Teirstein,et al.  Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. , 2015, The New England journal of medicine.

[15]  Hak Seung Lee,et al.  Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials. , 2016, JACC. Cardiovascular interventions.

[16]  W. Cheong,et al.  1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis , 2016, The Lancet.

[17]  Hiroki Shiomi,et al.  Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  G. Stone,et al.  Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[19]  Baris Gencer,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .

[20]  M. Togni,et al.  Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial. , 2017, International journal of cardiology.

[21]  M. Togni,et al.  Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. , 2015, Journal of the American College of Cardiology.

[22]  Bernard Chevalier,et al.  Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial , 2016, The Lancet.

[23]  P. Serruys,et al.  The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. , 2016, JACC. Cardiovascular interventions.

[24]  George F Borm,et al.  The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method , 2014, BMC Medical Research Methodology.

[25]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[26]  P. Teirstein,et al.  Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study. , 2000, Circulation.

[27]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[28]  B Meier,et al.  Angiographic follow-up after placement of a self-expanding coronary-artery stent. , 1991, The New England journal of medicine.

[29]  Heribert Schunkert,et al.  Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials , 2016, The Lancet.

[30]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[31]  P. Serruys,et al.  A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial , 2015, The Lancet.

[32]  F. Verheugt,et al.  Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.

[33]  C. Di Mario,et al.  ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. , 2014, JACC. Cardiovascular interventions.

[34]  A. Schmermund,et al.  Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. , 2016, Journal of the American College of Cardiology.

[35]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2015, BMJ : British Medical Journal.

[36]  S. Cook,et al.  Optical Coherence Tomography Findings in Bioresorbable Vascular Scaffolds Thrombosis , 2015, Circulation. Cardiovascular interventions.

[37]  Patrick W Serruys,et al.  Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. , 2015, European heart journal.

[38]  R. Whitbourn,et al.  Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Ev , 2014, JACC. Cardiovascular interventions.

[39]  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002 .

[40]  P. Serruys,et al.  Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents , 2015, Circulation. Cardiovascular interventions.

[41]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[42]  P. Serruys,et al.  TCT-49 Two-year clinical outcome of Everolimus-eluting bioresorbable scaffold vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. , 2016, Journal of the American College of Cardiology.

[43]  P. Serruys,et al.  Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial , 2015, European heart journal.